Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (April 2005)
22 slides from Compumedics's investor presentation, April 2005
Slide 1: Investor Presentation April 2005
Investor Presentation April 2005 1
Slide 2: Outline
Outline z Compumedics’ introduction of financial highlights z Performance highlights z Growth profile z Core products z Strategy working 2
Slide 3: Introduction - Key Milestones
Introduction - Key Milestones z Compumedics has an impressive track record of achievement : – 1995 Teijin appointed as Japanese distributor – 1995 NASA contracts won – 1995 Sleep Heart Health Study awarded – 1996 JAFCO equity investment – 1997 FDA approval for the P-Series – 1999 Teijin Limited equi
Slide 4: Introduction - The Sleep Industry
Introduction - The Sleep Industry z There are 84 known sleep disorders ranging from snoring to obstructive sleep apnea. – 84 known sleep disorders. Obstructive sleep apnea (25%+), PLM (10%), Insomnia (7%). z Over 20 million people in the USA are estimated to suffer from sleep apnea alone. z With 300
Slide 5: Financial Highlights Interim Dec 2004
Financial Highlights Interim Dec 2004 PROFIT z High investment levels in R&D and product development (18% of revenues), as a reflection of a strong sales outlook and product pipeline z Loss at the NPAT line of $0.8m compares with last year’s $1.1m profit. REVENUE z Record revenues of $19.2m for the
Slide 6: Performance Highlights – Dec end 04
Performance Highlights – Dec end 04 Acquisition of DWL in Singen, Germany. European base now established, positioning Europe for rapid growth outlook. Contributed $2.4m revenue for the period from 1 September, 2004. Key management secured by DWL business founders. 24 other staff. Secure IP b
Slide 7: Historical Sales Graph
Growth Profile - Historical Sales Graph AU$m 25 20 15 10 5 0 1H99 2H99 1H00 2H00 1H01 2H01 1H02 2H02 1H03 2H03 1H04 2H04 1h 05 Export Sales Domestic Sales Other Income Fact: Revenues for the last five years have grown an average: + 39% p.a. 7
Slide 8: Strong growth continues in USA
Growth Profile - Strong growth continues in USA 2004 Europe Asia 14% 23% 2005 Europe Australia Asia 18% 10% 17% USA 53% Australia 10% USA 55% 8
Slide 9: Compumedics – Global Company
Growth Profile - Compumedics – Global Company 9
Slide 10: Strategies
Growth Profile - Strategies • International market expansion of the core sleep business • Expansion of core sleep diagnostic and monitoring technology into the associated fields of neurology and cardiology • Expand recurring revenue base (sensors, electrodes and other consumables) • Growth opportuni
Slide 11: Some market facts
Growth Profile - Some market facts: Compumedics – Clinical Sleep and EEG z 40% of the Australian Clinical EEG Market and 70% of the Australian Sleep Diagnostics Market. z 10% USA market share and growing in sleep diagnostics. z Developed and installed Australia’s first computerised sleep centre at M
Slide 12: Strategy
Growth Profile - Strategy Strategy: Strategy: Our medium term objective is to see revenues at: Our long term strategy is to build on our current world leadership in sleep diagnostics to become a global leader in broader medical diagnostics #1 Sleep Diagnostic Specialist $100 M p.a. Fact: Sales in FY
Slide 13: A Big Market to Grow In
Growth Profile - A Big Market to Grow In High investment (18% of revenues) levels in R&D and product development continue, as a reflection of a strong sales outlook and product pipeline. 13
Slide 14: Distribution Channels
Growth Profile - Distribution Channels z USA sales are made direct to end-user customers by Compumedics staff. z Australian sales are made direct by Compumedics staff. z European sleep sales are undertaken by a network of distributors. Our main sleep distributor is Draeger Medical. z Asian sales are
Slide 15: Core Products
Core Products E-Series z New generation laboratory based diagnostic product for both full polysomnography (PSG) “sleep” studies and or separate EEG studies. Siesta z World leading portable diagnostic device with wireless capability for both sleep and general patient monitoring. Somté z Combined Slee
Slide 16: Core Products
Core Products SynAmps z The most sophisticated neurological amplifier available on the market. These amplifiers can be combined to obtain up to 256 channels of physiological data. Scan z Provides for the acquisition of the EEG and Evoked Potential data including a rich set of clinically popular and
Slide 17: Core Products - sample
Core Products - sample PRODUCT USAGE CUSTOMER BENEFITS APPROVAL PRICE POINT E-Series Sleep diagnosis Sleep laboratories New technology, FDA, CE, TGA $17,500 and EEG and hospital growing customer monitoring base Siesta Sleep monitoring Hospitals and Wireless, versatile, CE, TGA, FDA (2nd $35,000 and
Slide 18: Core Products - Moving Forward : Technologies
Core Products - Moving Forward : Technologies Curry 5.0 Siesta802 ComperioDQ Stim II z Strong product pipelines in all CMP divisions. z Medical Innovation breakthroughs now approaching patent and clinical proof of concept phase. 18
Slide 19: Strategy Working
Strategy Working DWL Blood Flow Neuroscan Diagnostics Sleep Diagnostics Neuro Neuro Diagnostics Medical Supplies Building a global medical diagnostic company z With Compumedics’ core strategic edge being Sleep Diagnostics and z Leveraging this technology into related fields including Neurosciences,
Slide 20: Moving Forward : Business
Moving Forward : Business Revenues expected to be around the $38 to $42m region for year ended June 30, 2005. Earnings after tax expected to be between $1 million and $3 million for year ended June 30, 2005. Revenue in the second half expected to be stronger over the first half in 2005 again a
Slide 21: Moving Forward : Business (cont’d)
Moving Forward : Business (cont’d) Europe positioned growth as infrastructure there is built in a similar way to that of the USA (organic growth and continued integration of DWL business). The cost efficiency programs and lean processes. Expanded and strengthened USA sales force with more new
Slide 22: Recap / Way Forward
Recap / Way Forward 1. Global technological and product leadership across sleep diagnostic, neurodiagnostic and cardiodiagnostic fields with strong growth opportunity as Compumedics continues to penetrate 1 billion per annum market. 2. Strong product pipelines and technology product leadership paves